ClinicalTrials.gg
CompletedNCT04786548Updated Oct 30, 2026

Neuroinflammation in Patients With OCD

A Phase 2 interventional study of Celecoxib in Obsessive-Compulsive Disorder, sponsored by New York State Psychiatric Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by New York State Psychiatric Institute · Phase 2, Interventional, and Other

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Obsessive-Compulsive Disorder by New York State Psychiatric Institute — 1 open to participants now, 1 under way, none of them phase 3. Obsessive-Compulsive Disorder · New York State Psychiatric Institute.

Enrollment
11th of 24
18 · median 16
Started
2021
the only one that year
Phase 2
9 of 24
none open now
Registered
22nd of 24
by date

Among the 24 studies in Obsessive-Compulsive Disorder by New York State Psychiatric Institute, this one is the 11th largest by enrollment, is the only one that started in 2021, is one of 9 in phase 2, and was the 22nd registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

1 of the 24 studies in Obsessive-Compulsive Disorder by New York State Psychiatric Institute is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obsessive-Compulsive Disorder by New York State Psychiatric Institute, or all of them as a file.
02

Study summary

The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.

Read the detailed description

Existing evidence-based treatments for adults with obsessive-compulsive disorder (OCD), including cognitive behavioral therapy and first-line medication-based treatment, do not fully resolve symptoms for a majority of patients. This study proposes to test a new treatment strategy for OCD, examining inflammation as one factor that may contribute to the development of OCD and that may be targeted with medication-based treatment. Recent findings using both brain imaging and analyses from blood samples suggest that some individuals with OCD have increased levels of inflammation in the brain, which may have negative effects on brain function, contributing to symptoms of OCD. Moreover, early clinical studies suggest that some medications with anti-inflammatory properties may be beneficial in treating OCD symptoms. An important and untested question is whether the degree of inflammation assessed using these biological tools can predict how much benefit individuals with OCD will derive from treatment with an anti-inflammatory medication. The investigators will measure inflammation in the brain using PET imaging and measures of inflammation in the body using blood tests in adults with OCD. Patients will then undergo 8 weeks of treatment with an anti-inflammatory medication with some evidence of clinical effectiveness in OCD, celecoxib. The investigators predict that OCD patients with greater evidence of inflammation at baseline, assessed by brain imaging and blood tests, will derive the greatest benefit from anti-inflammatory treatment. In addition, the investigators will compare these inflammatory markers with data from a group of healthy volunteers (collected as part of another protocol, IRB #6786), to extend earlier work finding elevated inflammatory markers in adult OCD. Finally, the investigators will examine whether celecoxib treatment in OCD patients results in reductions in measures of inflammation measured from blood samples and whether the degree of anti-inflammatory effect observed biologically is related to improvement in OCD symptoms. The ultimate goal of this line of research is to pave the way for more individually-tailored, effective treatments for adult OCD based on improved understandings of pathological targets, and to validate an anti-inflammatory approach to the treatment of OCD in individuals with evidence of inflammation.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Obsessive-Compulsive Disorder
  • OCD
  • Neuroinflammation
  • Nonsteroidal anti-inflammatory drug
  • Celecoxib
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 55 years old
  • Principal diagnosis of Obsessive-Compulsive Disorder (OCD)
  • Ongoing OCD symptoms despite current treatment with psychiatric medication
  • Capacity to provide

Exclusion criteria

Exclusion Criteria:

  • Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality)
  • Medical or neurological conditions that would increase risk of participation or impact research measures
  • to an MRI or PET scan (e.g., metal implants)
  • Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, , medications, or daily non-steroidal anti-inflammatory medications)
  • Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Celecoxib Treatment

    Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment

    Drug: Celecoxib

Interventions

  • Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.

    Also known as: Celebrex

06

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive Compulsive Scale

    The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a clinician-administered interview that measures the presence and severity of symptoms of Obsessive-Compulsive Disorder. It consists of 10 questions with scores ranging from 0 to 4, with a possible score ranging from 0 to 40. The primary measure of clinical improvement in this study is the Week 8 YBOCS score. In statistical models, we will co-vary for the Week 0 YBOCS score to account for baseline symptoms severity, but the Week 8 value is the primary outcome.

    Time frame: Week 8

Secondary outcomes

  1. TSPO Volume of Distribution assessed by PET imaging with [11C]ER-176

    We will perform PET imaging with the \[11C\]ER-176 radiotracer to quantify TSPO binding, a marker of neuroinflammation, quantified as the outcome measure Volume of Distribution (VT).

    Time frame: Baseline

  2. PGE2

    prostaglandin E2 levels will be measured in serum.

    Time frame: Baseline

  3. PGE2

    prostaglandin E2 levels will be measured in serum.

    Time frame: Week 8

  4. PGF2-alpha

    Prostaglandin F2-alpha levels will be measured in serum.

    Time frame: Week 0

  5. PGF2-alpha

    Prostaglandin F2-alpha levels will be measured in serum.

    Time frame: Week 8

  6. CRP

    C-reactive protein levels will be measured in serum.

    Time frame: Week 0

  7. CRP

    C-reactive protein levels will be measured in serum.

    Time frame: Week 8

07

Study locations

1 site
  • New York State Psychiatric Institute
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2021 to primary completion in Oct 2026, 66 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 8, 2021
StartActual
Apr 1, 2021
Primary completionActual
Oct 28, 2026was Aug 2026
CompletionActual
Oct 28, 2026was Aug 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Completed Reason for stopping removed
changed Oct 30, 2026
Primary completion
Aug 2026→Oct 28, 2026 (actual)
Oct 30, 2026
Study completion
Aug 2026→Oct 28, 2026 (actual)
Oct 30, 2026
Enrollment
21 (estimated)→18 (actual)
Oct 30, 2026
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedMILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead PanelTime frame: Baseline
  • RemovedMILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead PanelTime frame: Week 8
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Suspended→Completed
    Why stopped Reason for stopping removed
    Primary completion Aug 2026→Oct 28, 2026 (now actual)
    Study completion Aug 2026→Oct 28, 2026 (now actual)
    Enrollment 21 (estimated)→18 (actual)
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedMILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead PanelTime frame: Baseline
    • RemovedMILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead PanelTime frame: Week 8
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04786548
Responsible party
Jeffrey Miller (Associate Professor of Clinical Psychiatry, New York State Psychiatric Institute) — Principal investigator
First posted
Mar 8, 2021
Start date
Apr 1, 2021
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Oct 30, 2026

Study contacts

Jeffrey Miller, M.D.
principal investigator · New York State Psychiatric Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion